Summary With the association of 5-fluorouracil (5-FU) and alpha-interferon (IFN), objective responses as high as 26-63% have been reported in untreated patients with advanced colorectal cancer. However, grade 3-4 toxicity has also been reported. We have conducted a prospective phase II randomised study comparing 5-FU to 5-FU + IFN, to investigate whether the addition of IFN to a weekly 5-FU regimen devoid of significant toxicity used at our institutions could improve the effectiveness of 5-FU while maintaining acceptable toxicity. Patients with histologically proven advanced colorectal carcinoma were randomised to receive 5-FU 500 mg m-2 intravenous (i.v.) bolus on days 1-5 followed by 5-FU 500 mg m-2 i.v. bolus weekly from day 15, with or without IFN alpha-2a intramuscularly (i.m.) 1.5 mU daily on days 6-12 and 3 mU i.m. daily thereafter. The treatment was administered on an outpatient basis. Response was evaluated every 3 months, and treatment continued until progression or after two consecutive judgements of stable disease. Response rate was the main end point of the study. Of 141 patients eligible, 72 were randomised to 5-FU alone (arm A) and 69 to 5-FU+IFN (arm B). Responses were 9/72 (12.5%) in arm A and 6/69 (8.7%) in arm B; complete responses were three in arm A and two in arm B. Progression-free survival (median 4 months) and survival (median 12 months) were identical in the two arms. Toxicity was almost absent in arm A and moderate in arm B, represented mainly by haematological toxicity (usually leucopenia). In conclusion, overall survival was good in both arms of treatment and toxicity was moderate. While the response rate with 5-FU alone was in accord with the literature data, response to 5-FU + IFN was lower than expected. At least at this dosage and schedule, the association of 5-FU and IFN is no better than 5-FU alone and is of no clinical interest.
There is presently no standard treatment for advanced colorectal cancer. Treatment with 5-FU induces response rates of around 15-20%, while attempts at modulating 5-FU activity, or using aggressive combination chemotherapy, might result in an increased response rate but barely affect survival.
With the association of 5-FU and alpha-interferon (IFN) objective responses in 13/17 untreated patients were initially reported (Wadler et al., 1989) . Response rates ranging from 26% to 63% have subsequently been obtained in other trials (Kemeny et al., 1990; Wadler et al., 1991; Padzur et al., 1993) ; however, severe toxicity (grade 3-4) with the combination was also reported, including diarrhoea, neurolgical complications and toxic deaths. Futhermore, the impact of this combination on survival is not clear.
In October 1990 we started a prospective phase II randomised study comparing 5-FU with 5-FU + IFN in advanced, untreated colorectal carcinoma, with the aim of evaluating the effect on response and survival of the addition of IFN to a weekly 5-FU regimen of limited toxicity commonly administered on an outpatient basis at our institutions.
Patients and methods
Patients with histologically proven advanced colorectal cancer, evaluable disease, age <75 years, performance status ECOG 0-1, life expectancy of 3 months or more, and no previous chemotherapy, were randomised to receive 5-FU mg m-2 i.v. bolus (15 min infusion in saline) on days 1-5 and then weekly from day 15 (arm A); or 5-FU + IFN alpha-2a i.m. 6 mU day-' (arm B); IFN was started at day 6 and given at half dose for the first week. The initially planned IFN dose of 6 mU day-' was abandoned after 4 months of study, as a result of both systemic and haematological toxicity registered in the first patients, and a dose of 3 mU day-was used in the following patients. Response was evaluated every 3 months and treatment continued until progression or after two consecutive judgments of stable disease. Staging and follow-up clinical assessment included haematochemistry, tumour markers, abdominal computed tomography (CT) or ultrasound, chest radiograph, plus other tests depending on the site of involvement. Oral informed consent was a prerequisite for study entry.
Evaluation of response and toxicity was by standard criteria (Miller et al., 1981) . The following dose adjustments were applied: 5-FU was delayed by 1 week and IFN was given at half dose for WBC between 2 000 and 3 000 or platelets between 75 000 and 100 000; for lower values, 1 week delay for both drugs was required. Paracetamol 500-1000 mg orally was used in association with IFN, usually (Kaplan and Meier, 1958 ) and compared by the log-rank test (Peto and Peto, 1972 Protocol deviations were: two patients randomised to arm B were treated with aggressive platinum-based chemotherapy, since the origin of their tumour from the intestinal tract was not accepted as conclusive by the responsible physicians; one of these patients had a partial response (PR) followed by progression (P) at 26 months and is still alive 40 months from the start of treatment. One patient per arm over the age of 75 and in good general condition was randomised and evaluated, as well as two patients per arm with performance status ECOG 2 (Karnofsky 60).
Responses were 9/72 (12.5%) in arm A and 6/69 (8.7%) in arm B; 95% confidence limits showed wide overlap between the two groups (Table II) . The difference in response rates was 3.8% in favour of 5-FU alone; the 95% confidence interval for this difference was -8.4% to 16.0%. An advantage in favour of the combination of 5-FU + IFN higher than 8.4% can therefore be confidently excluded at the 95% level based on these data.
Complete responses (CR) were three in arm A and two in arm B. Progression-free survival (median 4 months) and survival (median 12 months) were identical in the two arms (Figures 1 and 2 ). Duration of response was 5-15 months in arm A; in arm B, four patients survived without progression for more than 20 months. Two of them were CR patients with disease involving liver and distant nodes, and liver and Response by site of involvement is depicted in (Peters and van Groningen 1992) .
One of these recently introduced 5-FU modulators is ainterferon. After the experimental demonstration that IFN is able to increase the anti-tumour activity of 5-FU (Pfeffer and Tamm, 1984; Elias and Sandoval, 1989; Chu et al., 1990; Danhauser et al., 1993; Houghton et al., 1993) , several (1989) were not completely confirmed by others, a response rate of 30-40% was commonly observed; however, severe associated toxicity (mucositis, diarrhoea, leucopenia, neurological impairment and toxic deaths) was also reported (Kemeny et al., 1990; Wadler et al., 1991; Pazdur et al., 1993) , while the effect on survival is entirely unclear. In addition, optimal doses and schedules have yet to be identified.
The aim of the present study was to evaluate the contribution of IFN to the clinical activity of a weekly administration of 5-FU, devoid of relevant toxicity and given entirely on an outpatient basis, commonly employed at our institutions as palliative treatment of advanced colorectal cancer. The dosage of 5-FU was in the range of clinical effectiveness yet with low toxicity (500 mg m-2 weekly); schemes of equivalent dose intensity have been reported effective and are currently used in clinical trials (Lokich et al., 1989; Leichman et al., 1995) .
The dosage of IFN was the maximum allowed in our patients. A dose of 6 mU day-' (42 mU per week) was planned, but was shown in the first patients treated in our study not to be feasible; most of the patients received 3 mU day-1. The results obtained in our study showed a response rate to the combination similar to that obtained with 5-FU alone, with identical time to progression and overall survival. Several theorectical reasons might explain this failure of IFN to improve the effectiveness of 5-FU. One of these could be the use of a lower dose of IFN than that employed in the original scheme by Wadler et al. (1989) . However, the few phase II studies employing low-dose IFN showed low toxicity and a response rate close to 30% (Botto et al., 1991; Hansen et al., 1993; Meehan et al., 1993) .
Another possible cause could be our choice of giving 5-FU by bolus injections (even in the loading course). However, on the basis of literature data (John et al., 1993; Pazdur et al., 1993; Leichman et al., 1995) , it is unlikely that such a difference in activity could be explained by this change of schedule only.
Contrasting results have been reported in randomised trials comparing 5-FU to 5-FU + IFN, with one study in which responses were higher with the combination (26.8% vs 10.1% with 5-FU alone) and also survival analysis showed a moderate but significant advantage in favour of the combination (Dreyfus et al., 1995) . In the majority of studies the 5-FU/IFN combination failed to show any therapeutic improvement compared with 5-FU alone, while the incidence and severity of toxicity was significantly higher (York et al., 1993; Corfu-A Study Group, 1995; Hill et al., 1995) . Increase in incidence of toxic effects, without increase in response rates, was also recorded when IFN was added to a 5-FU/leucovorin combination in randomised trials (Seymour et al., 1994; Kohne et al., 1995) .
Furthermore, in our study, despite the use of a combination of 5-FU and IFN of moderate toxicity, a dose reduction was often required for both drugs because of toxicity, and the attempts to use IFN at a higher dosage soon had to be abandoned. In conclusion. the addition of IFN to 5-FU at doses of the two drugs devoid of significant toxic effects did not result in improved efficacy with respect to 5-FU alone. As was recently stressed (Kemeny. 1995) . the heterogeneity of the patients with advanced colorectal cancer might account for the vanability of response rates and survival in this disease and the difficulty of obtaining univocal results in clinical trials. Since advanced colorectal carcinoma is a condition in which survival times seem to be independent from any presently available medical treatment, the attempts at improving response rates, by testing more toxic and expensive combinations should be limited to expenrmental clinical setting and avoided in routine clinical practice.
